| Literature DB >> 27186137 |
Abstract
We studied the absolute bioavailability of calcium from calcium L-lactate in mice using pharmacokinetics, and reviewed the absolute bioavailability of calcium from three other calcium salts in mice previously studied: calcium chloride, calcium acetate, and calcium ascorbate. The results showed that calcium metabolism is linear between intravenous administration of 15 mg/kg and 30 mg/kg, and is not affected by anions. Results after oral calcium administration of 150 mg/kg showed that the intestinal absorption process was significantly different among the four calcium salts. The rank of absolute bioavailability of calcium was calcium ascorbate > calcium L-lactate ≥ calcium acetate > calcium chloride. The mean residence time (MRTab) of calcium from calcium ascorbate (32.2 minutes) in the intestinal tract was much longer than that from calcium L-lactate (9.5 minutes), calcium acetate (15.0 minutes) and calcium chloride (13.6 minutes). Furthermore, the foods di-D-fructo-furanose-1,2':2,3'-dianhydride, sudachi (Citrus sudachi) juice, and moromi-su (a Japanese vinegar) increased the absolute bioavailability of calcium from calcium chloride by 2.46-fold, 2.86-fold, and 1.23-fold, respectively, and prolonged MRTab by 48.5 minutes, 43.1 minutes, and 44.9 minutes, respectively. In conclusion, the prolonged MRTab of calcium in the intestinal tract by anion or food might cause the increased absorbability of calcium.Entities:
Keywords: DFA III; absolute bioavailability of calcium; calcium L-lactate; calcium chloride; pharmacokinetics; sudachi juice
Year: 2013 PMID: 27186137 PMCID: PMC4863542 DOI: 10.2147/JEP.S49668
Source DB: PubMed Journal: J Exp Pharmacol ISSN: 1179-1454
Calcium absorbability from calcium salts measured by mass balance method
| Calcium salts | Absorbability (%) | Animals, condition | References |
|---|---|---|---|
| Calcium carbonate | 23.5 ± 12.3 | Fast | Heaney |
| 39 ± 7 | Human | Martin | |
| 29.6 ± 5.4 | Diet | Patrick | |
| 23.5 ± 12.3 | Fast | Patrick | |
| 39 ± 3 | Human | Sheikh | |
| 14.7 ± 6.4 | Human | Uenishi | |
| Calcium citrate | 24 ± 4.9 | Fast | Heaney |
| 24.2 ± 4.9 | Fast | Patrick | |
| 30 ± 3 | Human | Sheikh | |
| Calcium citrate malate | 36.3 ± 7.6 | Diet | Patrick |
| 36.3 ± 7.6 | Diet | Heaney | |
| Calcium sulfate | 41 ± 7 | Human | Martin |
| Calcium lactate | 47 ± 8 | Human | Martin |
| 32 ± 4 | Human | Sheikh | |
| Calcium oxalate | 10.2 ± 4.0 | Diet | Patrick |
| Tricalcium phosphate | 25.2 ± 13.0 | Diet | Patrick |
| Calcium acetate | 32 ± 4 | Human | Sheikh |
| Calcium gluconate | 27 ± 3 | Human | Sheikh |
| Calcium carbonate | 27.42 ± 3.09 | Rat | Weaver |
| Calcium citrate | 28.69 ± 2.25 | Rat | Weaver |
| Calcium citrate malate | 28.06 ± 1.58 | Rat | Weaver |
| Calcium fumalate | 30.09 ± 1.02 | Rat | Weaver |
| Calcium malate fumalate | 29.13 ± 1.65 | Rat | Weaver |
Pharmacokinetic parameters of calcium in mice after IV or oral administration of calcium chloride, calcium acetate, or calcium ascorbate
| Salts | Dose (mg/kg) | AUCIV (μg/mL) | MRTIV (minutes) | CLIV (mL/minute/kg) | Vdss (mL/kg) |
|---|---|---|---|---|---|
| IV administration | |||||
| CaCl2 | 15 | 1484.5 ± 41.0 | 29.3 ± 1.3 | 10.1 ± 0.3 | 296.5 ± 8.5 |
| 30 | 2870.6 ± 90.8 | 33.0 ± 1.1 | 10.5 ± 0.3 | 345.1 ± 15.8 | |
| CaAc2 | 15 | 1507.9 ± 128.4 | 29.1 ± 2.0 | 10.0 ± 0.9 | 289.9 ± 7.4 |
| 30 | 2637.2 ± 121.6 | 30.0 ± 2.4 | 11.4 ± 0.5 | 340.9 ± 24.7 | |
| CaAs2 | 15 | 1193.9 ± 101.7 | 30.4 ± 1.0 | 12.6 ± 1.1 | 383.6 ± 20.9 |
| 30 | 2711.3 ± 154.2 | 32.5 ± 1.2 | 11.0 ± 0.6 | 359.2 ± 34.7 | |
| CaLc2 | 15 | 1396.2 ± 104.4 | 28.4 ± 2.0 | 10.8 ± 0.8 | 305.8 ± 29.3 |
| 30 | 3139.8 ± 123.1 | 31.9 ± 2.1 | 9.6 ± 0.4 | 304.2 ± 10.4 | |
| Means | 30.6 ± 1.7 | 10.8 ± 1.0 | 328.2 ± 33.9 |
Note: Each value represents the mean ± standard deviation (n = 4).
Abbreviations: IV, intravenous; AUC, area under the curve; MRT, mean residence time; CL, plasma clearance; Vdss, volume of distribution; CaCl2, calcium chloride; CaAc2, calcium acetate; CaAs2, calcium ascorbate; CaLc2, calcium L-lactate; Tmax, time to reach the maximum plasma concentration; Cmax, maximum plasma concentration; Fabs, absolute bioavailability; n, number.
Pharmacokinetic parameters of calcium in female mice after IV or oral administration of calcium
| Mice | AUCIV (μg/mL · minute) | MRTIV (minutes) | CLIV (mL/minute/kg) | Vdss (mL/kg) | |
|---|---|---|---|---|---|
| IV administration (dose: 30 mg/kg) | |||||
| SHAM | 2101.0 ± 14.3 | 27.1 ± 3.6 | 14.3 ± 0.9 | 386.0 ± 23.8 | |
| OVX | 2097.0 ± 10.5 | 26.5 ± 1.9 | 14.3 ± 0.7 | 379.0 ± 34.0 | |
| Oral administration (dose: 150 mg/kg) | |||||
| SHAM | 30 | 93.0 ± 2.5 | 1121.0 ± 22.8 | 57.2 ± 4.2 | 10.7 ± 2.8 |
| OVX | 30 | 94.0 ± 1.9 | 1086.0 ± 20.1 | 45.3 ± 2.9 | 10.3 ± 2.1 |
| SHAM + HJ | 30 | 104.0 ± 3.8 | 2091.0 ± 80.6 | 76.8 ± 2.4 | 19.9 ± 3.1 |
| OVX + HJ | 30 | 104.0 ± 2.5 | 2120.0 ± 71.7 | 75.4 ± 5.6 | 20.2 ± 1.7 |
Notes: Each value represents the mean ± standard deviation (n = 5).
Dose refers to a quantity of calcium in the CaCl2 solution; the pharmacokinetic parameters of calcium in male mice (ddY strain) were obtained from Ueda and Taira.22
Abbreviations: IV, intravenous; AUC, area under the curve; MRT, mean residence time; CL, plasma concentration; Vdss, volume of distribution; SHAM, sham-operated mice; OVX, ovariectomized rats; Tmax, time to reach maximum plasma concentration; Cmax, maximum plasma concentration; Fabs, absolute bioavailability; HJ, Hachimi-jio-gan extract.
Figure 1Time course of plasma calcium concentrations after intravenous calcium administration of 15 mg/kg or 30 mg/kg of body weight of calcium L-lactate.
Notes: (A) Open circles refer to plasma calcium concentrations after administration of 30 mg/kg of body weight, closed circles refer to calcium administration of 15 mg/kg of body weight, and open squares are the plasma calcium concentrations of the control mice. (B) In total, 150 mg/kg of body weight of calcium L-lactate in 1% solution was orally delivered to the duodenum and blood was collected. Open circles refer to plasma calcium concentrations after oral administration of one of the three calcium salts, and open squares are the plasma calcium concentrations of the control mice. Data points represent the mean ± standard deviation (n = 4).
Abbreviation: n, number.
Figure 2Effect of the foods DFA III, sudachi juice, and moromi-su on the absolute bioavailability of calcium of 150 mg/kg from CaCl2.
Notes: (A) CaCl2 + DFA III; (B) CaCl2 + sudachi juice; and (C) CaCl2 + moromi-su. CaCl2 + food means that food was orally administered, following oral administration of 150 mg of calcium per kg from CaCl2, and blood samples were collected. Closed circles refer to plasma calcium concentrations after oral administration of food and calcium chloride, and open circles are the plasma calcium concentrations after oral administration of CaCl2. Data points represent the mean ± standard deviation (n = 4).
Abbreviations: DFA III, di-D-fructo-furanose-1,2′:2,3′-dianhydride; CaCl2, calcium chloride; n, number.
Effect of foods on pharmacokinetic parameters of calcium in male mice after oral administration of calcium chloride
| Foods | Tmax (minutes) | Cmax (μg/mL) | AUCoral (μg/mL · minute) | MRToral (minute) | Fabs (%) |
|---|---|---|---|---|---|
| Oral administration (dose: 150 mg/kg) | |||||
| DFA III | 45 | 94.1 ± 15.3 | 2013.5 ± 20.1 | 81.5 ± 7.9 | 14.0 ± 2.1 |
| Sudachi juice | 45 | 101.3 ± 21.1 | 2343.2 ± 22.8 | 76.2 ± 4.2 | 16.3 ± 2.8 |
| Moromi-su | 45 | 115.5 ± 32.8 | 997.3 ± 80.6 | 78.3 ± 8.4 | 7.0 ± 3.1 |
Note: Each value represents the mean ± standard deviation (n = 4).
Abbreviations: Tmax, time to reach maximum plasma concentration; Cmax, maximum plasma concentration; AUC, area under the curve; MRT, mean residence time; Fabs, absolute bioavailability; DFA III, di-D-fructo-furanose-1,2′:2,3′-dianhydride; n, number.